VRTX VERTEX PHARMACEUTICALS INC
2026Q1 · CUSIP 92532F100 · Sector: Healthcare & Biotech
Lit · Institutions accelerating in
Holders
1,672
Δ holders QoQ
+18
Breadth percentile
Top 17%
Whale holders
336
Δ whales
-4
Inst. holding value
$100.5B
New positions
154
Closed positions
136
Price momentum (1Q)
-8.5%
Put / Call
30/34
Breadth history (34 quarters)
Past Lit Events & Aftermath 18 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2026Q1 | Top 17% | — | — |
| 2025Q4 | Top 2% | -8.5% | — |
| 2025Q1 | Top 2% | -11.3% | -1.5% |
| 2024Q2 | Top 3% | +1.4% | -1.2% |
| 2024Q1 | Top 3% | +9.6% | +4.6% |
| 2023Q4 | Top 2% | +5.5% | +15.6% |
| 2023Q2 | Top 1% | +7.7% | +24.1% |
| 2022Q4 | Top 2% | +16.2% | +18.1% |
Options Sentiment
Put holders
30
QoQ: -1
Call holders
34
QoQ: +3
See methodology →
Fundamentals
PE (TTM)
28.8
EPS (TTM)
$16.85
EPS YoY
—
Revenue (TTM)
$12.2B
Revenue YoY
+10.1%
Net margin
35.5%
ROE
22.4%
Debt ratio
26.9%
FCF (TTM)
$3.7B
Dividend (TTM)
No dividend
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
P/E (TTM) over time
P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden
As of 2026-03-31 · SEC filings (XBRL)
Get the next update
2026Q2 holdings publish around Aug 15 — subscribe to receive the lists first.